restrictin-P
produced by MBA-2.1 cells; inhibitory to the growth of plasmacytomas & mature B cell lymphomas
Networked: 4
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Plasmacytoma
01/01/1991
- " MBA-2.1 cells produce an activity, designated restrictin-P, which is specifically inhibitory to the growth of plasmacytomas and mature B cell lymphomas. " 12/08/1995
- " Thus, in this study, we identified the plasmacytoma growth inhibitor, restrictin-P, as being activin A of stromal origin. " 01/01/1995
- " X-ray microanalysis of intracellular ions revealed an increase in calcium ions, following exposure of plasmacytoma cells to restrictin-P, accompanied by a decrease in phosphor ions. " 12/08/1995
- " The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. " 01/01/1995
- " We have recently found that the inhibitor of plasmacytoma cell growth, restrictin-P, is a stroma derived activin A and that it is an antagonist of interleukin-6 and interleukin-11. "
|
2. | B-Cell Lymphoma (Lymphoma, B Cell)
|
3. | Hepatocellular Carcinoma (Hepatoma)
|
|
Related Drugs and Biologics